Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

  1. Aroda, V.R.
  2. Ahmann, A.
  3. Cariou, B.
  4. Chow, F.
  5. Davies, M.J.
  6. Jódar, E.
  7. Mehta, R.
  8. Woo, V.
  9. Lingvay, I.
Revista:
Diabetes and Metabolism

ISSN: 1878-1780,  1262-3636

Ano de publicación: 2019

Volume: 45

Número: 5

Páxinas: 409-418

Tipo: Revisión

DOI: 10.1016/J.DIABET.2018.12.001 GOOGLE SCHOLAR
Fonte de datos: Scopus